Terms: = Breast cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Treatment
271 results:
1. The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort study.
Ziser KED; Wood S; Tan GSQ; Morton JI; Shaw JE; Bell JS; Ilomaki J
J Diabetes; 2024 Apr; 16(4):e13507. PubMed ID: 38599885
[TBL] [Abstract] [Full Text] [Related]
2. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.
Gerosa R; De Sanctis R; Jacobs F; Benvenuti C; Gaudio M; Saltalamacchia G; Torrisi R; Masci G; Miggiano C; Agustoni F; Pedrazzoli P; Santoro A; Zambelli A
Crit Rev Oncol Hematol; 2024 Apr; 196():104324. PubMed ID: 38462150
[TBL] [Abstract] [Full Text] [Related]
3. Novel 2 Gene Signatures Associated With breast cancer Proliferation: Insights From Predictive Differential Gene Expression Analysis.
Ibrahim A; Toss MS; Alsaleem M; Makhlouf S; Atallah N; Green AR; Rakha EA
Mod Pathol; 2024 Feb; 37(2):100403. PubMed ID: 38104894
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China.
Ren M; Cai X; Jia L; Bai Q; Zhu X; Hu X; Wang Q; Luo Z; Zhou X
BMC Cancer; 2023 Dec; 23(1):1175. PubMed ID: 38041048
[TBL] [Abstract] [Full Text] [Related]
5. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab.
Franco AFDV; Malinverni ACM; Waitzberg AFL
Pathol Res Pract; 2023 Dec; 252():154917. PubMed ID: 37977031
[TBL] [Abstract] [Full Text] [Related]
6. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
[TBL] [Abstract] [Full Text] [Related]
7. mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers.
Bouamar H; Broome LE; Lathrop KI; Jatoi I; Brenner AJ; Nazarullah A; Gorena KM; Garcia M; Chen Y; Kaklamani V; Sun LZ
Breast Cancer Res; 2023 Oct; 25(1):131. PubMed ID: 37904250
[TBL] [Abstract] [Full Text] [Related]
8. Low-Density Lipoprotein Contributes to Endometrial Carcinoma Cell Proliferation, Migration, and Invasion by Activating the JAK-STAT Signaling Pathway.
Shen L; Zhang C; Cui K; Liang X; Zhu G
Anal Cell Pathol (Amst); 2023; 2023():4015167. PubMed ID: 37900720
[TBL] [Abstract] [Full Text] [Related]
9. Developing and Validating a Multivariable Prognostic-Predictive Classifier for treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study.
Mehanna H; Rapozo D; von Zeidler SV; Harrington KJ; Winter SC; Hartley A; Nankivell P; Schache AG; Sloan P; Odell EW; Thavaraj S; Hunter KD; Shah KA; Thomas GJ; Long A; Amel-Kashipaz R; Brown RM; Conn B; Hall GL; Matthews P; Weir J; Yeo Y; Pring M; West CML; McCaul J; Golusinski P; Sitch A; Spruce R; Batis N; Bryant JL; Brooks JM; Jones TM; Buffa F; Haider S; Robinson M
Clin Cancer Res; 2024 Jan; 30(2):356-367. PubMed ID: 37870417
[TBL] [Abstract] [Full Text] [Related]
10. Sclareol induces cell cycle arrest and ROS-mediated apoptosis and ferroptosis in lung adenocarcinoma cells.
Rah B; Shafarin J; Hamad M; Muhammad JS
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23563. PubMed ID: 37850667
[TBL] [Abstract] [Full Text] [Related]
11. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
André F; Su F; Solovieff N; Hortobagyi G; Chia S; Neven P; Bardia A; Tripathy D; Lu YS; Lteif A; Taran T; Babbar N; Slamon D; Arteaga CL
Ann Oncol; 2023 Nov; 34(11):1003-1014. PubMed ID: 37673211
[TBL] [Abstract] [Full Text] [Related]
12. Feasibility of 5-fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias (CIN) 2/3.
Desravines N; Hsu CH; Mohnot S; Sahasrabuddhe V; House M; Sauter E; O'Connor S; Bauman JE; Chow HS; Rahangdale L
Int J Gynaecol Obstet; 2023 Dec; 163(3):862-867. PubMed ID: 37431689
[TBL] [Abstract] [Full Text] [Related]
13. Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric cancer.
Maron SB; Chatila W; Walch H; Chou JF; Ceglia N; Ptashkin R; Do RKG; Paroder V; Pandit-Taskar N; Lewis JS; Biachi De Castria T; Sabwa S; Socolow F; Feder L; Thomas J; Schulze I; Kim K; Elzein A; Bojilova V; Zatzman M; Bhanot U; Nagy RJ; Lee J; Simmons M; Segal M; Ku GY; Ilson DH; Capanu M; Hechtman JF; Merghoub T; Shah S; Schultz N; Solit DB; Janjigian YY
Clin Cancer Res; 2023 Sep; 29(18):3633-3640. PubMed ID: 37406106
[TBL] [Abstract] [Full Text] [Related]
14. OTUD1 chemosensitizes triple-negative breast cancer to doxorubicin by modulating p16 expression.
Zhou T; Wu Y; Qian D; Tang H; Liu X; Qiu J; Wang D; Hong W; Meng X; Zheng Q
Pathol Res Pract; 2023 Jul; 247():154571. PubMed ID: 37257246
[TBL] [Abstract] [Full Text] [Related]
15. Etiologies and Outcome of Patients with Solid Tumors Admitted to ICU with Acute Respiratory Failure: A Secondary Analysis of the EFRAIM Study.
Benguerfi S; Dumas G; Soares M; Meert AP; Martin-Loeches I; Pene F; Bauer P; Mehta S; Metaxa V; Burghi G; Kouatchet A; Montini L; Mokart D; Van de Louw A; Azoulay E; Lemiale V;
Respir Care; 2023 Jun; 68(6):740-748. PubMed ID: 37072164
[TBL] [Abstract] [Full Text] [Related]
16. DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors.
Laranjeira ABA; Hollingshead MG; Nguyen D; Kinders RJ; Doroshow JH; Yang SX
Sci Rep; 2023 Apr; 13(1):5964. PubMed ID: 37045940
[TBL] [Abstract] [Full Text] [Related]
17. A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy.
El-Sadoni M; Shboul SA; Alhesa A; Shahin NA; Alsharaiah E; Ismail MA; Ababneh NA; Alotaibi MR; Azab B; Saleh T
Cancer Chemother Pharmacol; 2023 Apr; 91(4):345-360. PubMed ID: 36964435
[TBL] [Abstract] [Full Text] [Related]
18. Cellular senescence in the response of HR
Klapp V; Buqué A; Bloy N; Sato A; Yamazaki T; Zhou XK; Formenti SC; Galluzzi L; Petroni G
J Transl Med; 2023 Feb; 21(1):110. PubMed ID: 36765430
[TBL] [Abstract] [Full Text] [Related]
19. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
Harding JJ; Piha-Paul SA; Shah RH; Murphy JJ; Cleary JM; Shapiro GI; Quinn DI; Braña I; Moreno V; Borad M; Loi S; Spanggaard I; Park H; Ford JM; Arnedos M; Stemmer SM; de la Fouchardiere C; Fountzilas C; Zhang J; DiPrimeo D; Savin C; Duygu Selcuklu S; Berger MF; Eli LD; Meric-Bernstam F; Jhaveri K; Solit DB; Abou-Alfa GK
Nat Commun; 2023 Feb; 14(1):630. PubMed ID: 36746967
[TBL] [Abstract] [Full Text] [Related]
20. Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
Wilkins A; Gusterson B; Tovey H; Griffin C; Stuttle C; Daley F; Corbishley CM; Dearnaley D; Hall E; Somaiah N
EBioMedicine; 2023 Feb; 88():104436. PubMed ID: 36708693
[TBL] [Abstract] [Full Text] [Related]
[Next]
